Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapse/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase 3 trial.
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapse/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase 3 trial.
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-11-04
DOI
10.1016/j.annonc.2023.10.095
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the phase 2 randomized ROSEWOOD trial.
- (2022) Pier Luigi Zinzani et al. JOURNAL OF CLINICAL ONCOLOGY
- IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study
- (2022) Elizabeth L Budde et al. Clinical Lymphoma Myeloma & Leukemia
- Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
- (2021) Martin Hutchings et al. JOURNAL OF CLINICAL ONCOLOGY
- Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
- (2021) Caron A Jacobson et al. LANCET ONCOLOGY
- PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma
- (2020) Vladimir Sapon-Cousineau et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups
- (2020) Connie L. Batlevi et al. Blood Cancer Journal
- Long Term Follow-Up of Lenalidomide and Rituximab as Initial Treatment of Follicular Lymphoma
- (2020) Paolo Strati et al. BLOOD
- Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma
- (2020) Arne Kolstad et al. Blood Advances
- Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2020) M. Dreyling et al. ANNALS OF ONCOLOGY
- AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
- (2019) John P. Leonard et al. JOURNAL OF CLINICAL ONCOLOGY
- Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study
- (2019) Emmanuel Bachy et al. JOURNAL OF CLINICAL ONCOLOGY
- Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study
- (2019) Franck Morschhauser et al. Lancet Haematology
- Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis
- (2018) Carla Casulo et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma
- (2018) Stefano Luminari et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
- (2018) Franck Morschhauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of febrile neutropaenia: ESMO Clinical Practice Guidelines†
- (2016) J. Klastersky et al. ANNALS OF ONCOLOGY
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms
- (2016) S. H. Swerdlow et al. BLOOD
- Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2015) Thomas J. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
- (2013) Mathias J Rummel et al. LANCET
- The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
- (2011) E. Campo et al. BLOOD
- Safety and Efficacy of Combination Therapy with Fludarabine, Mitoxantrone, and Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan and Maintenance Rituximab as Front-Line Therapy for Patients With Follicular or Marginal Zone Lymphoma
- (2011) Reem Karmali et al. Clinical Lymphoma Myeloma & Leukemia
- Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
- (2010) Gilles Salles et al. LANCET
- Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma
- (2008) Franck Morschhauser et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma
- (2008) Robert Marcus et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started